Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

被引：1
|
作者：
Mienko, Fiona [1 ]
Halmos, Balazs [1 ]
Cheng, Haiying [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 12期
关键词：
PERFORMANCE STATUS; NIVOLUMAB; DOCETAXEL; EFFICACY;
D O I：
10.21037/atm.2020.02.68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Hamai, Kosuke
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    THORACIC CANCER, 2022, 13 (11) : 1611 - 1618
  • [32] The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Zhang, Shuling
    Bai, Xueli
    Shan, Fengping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [33] Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
    Kallergi, Galatea
    Vetsika, Eleni-Kyriaki
    Aggouraki, Despoina
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Koinis, Filippos
    Katsarlinos, Panagiotis
    Trypaki, Maria
    Messaritakis, Ippokratis
    Stournaras, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [34] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [35] Polled analysis of nivolumab for the treatment of advanced non-small cell lung cancer and the role of PD-L1 as a biomarker
    Aguiar, P.
    Santoro, I.
    Tadokoro, H.
    Filardi, B. A.
    Lopes, G. L.
    Picon, F. S.
    Noia Barreto, C. M.
    Muniz, P. C.
    Borges, A. M.
    Oliveira, P.
    Mountzios, G.
    Riera, R.
    De Mello, R. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S624 - S624
  • [36] PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients
    Yu, Y.
    Xia, L.
    Zhou, J.
    Wang, K.
    Zhang, Y.
    Zhang, C.
    Liu, A.
    Fan, Y.
    Chang, J.
    Wang, L.
    Liu, Y.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S778 - S778
  • [37] COST-EFFECTIVENESS AND BUDGET IMPACT OF PEMBROLIZUMAB MONOTHERAPY AS THE FIRST-LINE TREATMENT FOR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥ 50% IN THAILAND
    Thamlikitkul, L.
    Leelavanich, D.
    Krairojananan, W.
    Chamnanreong, R.
    Sriuranpong, V
    VALUE IN HEALTH, 2024, 27 (06) : S68 - S69
  • [38] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [39] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [40] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
12345